Patents by Inventor James E. Talmadge

James E. Talmadge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIMICROBIAL OZONE COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210400981
    Abstract: Antimicrobial aqueous ozone compositions and methods of use thereof are provided.
    Type: Application
    Filed: July 24, 2019
    Publication date: December 30, 2021
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: James E. Talmadge, Michael Draper, Holly Britton, Andrew M. Worlie, Evan D. Marlow
  • Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
    Patent number: 6649189
    Abstract: A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first biocompatible polymer from being dissolved in vivo following administration to a host.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: November 18, 2003
    Assignee: RxKinetix, Inc.
    Inventors: James E. Talmadge, Gary J. Rosenthal, Jeffrey B. Etter
  • Use of tumor necrosis factor as an adjuvant
    Patent number: 6551585
    Abstract: Tumor necrosis factors, alone or together with cytokines such as IL-1 or IFN-&ggr;, are capable of serving as non-toxic vaccine adjuvants.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 22, 2003
    Assignees: Genentech, Inc., National Institutes of Health, The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Michael Shepard, James E. Talmadge
  • Purging of stem cell products
    Patent number: 6475481
    Abstract: Methods for purging stem cell products of tumor cells and for treating an individual having a disease which is treated by myeloablative therapy and stem cell rescue using a purged product are provided.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: November 5, 2002
    Assignee: Canji, Inc.
    Inventor: James E. Talmadge
  • Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
    Publication number: 20020028515
    Abstract: A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first biocompatible polymer from being dissolved in vivo following administration to a host.
    Type: Application
    Filed: June 26, 2001
    Publication date: March 7, 2002
    Inventors: James E. Talmadge, Gary J. Rosenthal, Jeffrey B. Etter
  • Anti-inflammatory polypeptide antagonists of human I1-8
    Patent number: 5912232
    Abstract: Polypeptides derived from human interleukin-8 (IL-8) or other alpha chemokines which act as anti-inflammatory agents for the therapy of autoimmune disease, inflammatory conditions, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: June 15, 1999
    Assignee: Board of Regents of the University of Nebraska
    Inventor: James E. Talmadge
  • Polypeptide agonists for human interleukin-8
    Patent number: 5877276
    Abstract: Polypeptides derived from human interleukin-8 (IL-8) which act as therapeutic agents for the therapy of neoplastic (both solid and leukemic) and infectious diseases such as bacterial, fungal, viral and parasitic.
    Type: Grant
    Filed: April 28, 1997
    Date of Patent: March 2, 1999
    Assignee: The Board of Regents of the University of Nebraska
    Inventor: James E. Talmadge
  • Polypeptide agonists for human interleukin-8
    Patent number: 5627156
    Abstract: Polypeptides derived from human interleukin-8 (IL-8) which act as therapeutic agents for the therapy of neoplastic (both solid and leukemic) and infectious diseases such as bacterial, fungal, viral and parasitic.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: May 6, 1997
    Assignee: University of Nebraska Board of Regents
    Inventor: James E. Talmadge
  • Hemoregulatory peptides
    Patent number: 5620957
    Abstract: The invention provides compounds of the general formula: ##STR1## The compounds have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
    Type: Grant
    Filed: January 8, 1993
    Date of Patent: April 15, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Pradip K. Bhatnagar, William F. Huffman, James E. Talmadge
  • Use of tumor necrosis factor (TNF) as an adjuvant
    Patent number: 4963354
    Abstract: Tumor necrosis factors, alone or together with cytokines such as IL-1 or INF-.gamma., are capable of serving as non-toxic vaccine adjuvants.
    Type: Grant
    Filed: January 21, 1987
    Date of Patent: October 16, 1990
    Assignee: Genentech, Inc.
    Inventors: H. Michael Shepard, James E. Talmadge